PR Newswire PharmaOriginal article
ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
Phase 2approvedziresovirPositive
AI Analysis
Summary
ArkBio announced FDA approval for ziresovir (AK0529) to advance to Phase II clinical trials in severely ill RSV-infected infant patients. The approval enables the company to initiate human testing of its RSV antiviral candidate.
Clinical Trial Data
Phase
Phase II
Outcome Details
FDA approved ziresovir for Phase II clinical trial in severely ill RSV infected infant patients
Importance:6/10
Sentiment:
0.80
RSVantiviralpediatricFDA approvalChina
Read the original article
Published by PR Newswire Pharma on August 14, 2026 10:34 AM